Skip to main content

Table 2 Comparison between patients with major bleeding or ICH, minor bleeding and no bleeding

From: Warfarin and fibrinolysis - a challenging combination: an observational cohort study

  ICH or major bleeding, n = 7 Minor bleeding, n = 7 No bleeding, n = 22
Age (years)* 69 (63-72) 67 (61-78) 70 (62-79)
Sex; men 7 (100%) 5 (70%) 16 (73%)
Earlier fibrinolysis 0 3 (43%) 6 (27%)
Contraindication for fibrinolysis (other than warfarin) 1 (14%) 0 3 (18%)
Systolic BP* 126 (105-141) 127 (90-140) 122 (111-140)
Diastolic BP* 64 (61-92) 69 (60-81) 76 (70-90)
Fibrinolytic agent    
   streptokinase 1 (14.3%) 0 5 (23%)
   tPA (alteplase) 1 (14.3%) 1 (14.3%) 1 (4.5%)
   reteplase 5 (71.4%) 5 (71.4%) 13 (59%)
   tenecteplase 0 1 (14.3%) 3 (13.5%)
Adjuvant medication    
   aspirin 1 (14%) 3 (43%) 15 (68%)
   heparin 5 (71%) 5 (71%) 14 (64%)
UFH 3 (43%) 1 (14%) 2 (9%)
LMWH 2 (29%) 4 (57%) 12 (55%)
LMWH (i.v.+s.c.) 1 (14%) 2 (29%) 3 (14%)
LMWH only i.v. 1 (14%) 2 (29%) 6 (27%)
LMWH reduced dose s.c 0 0 3 (14%)
Laboratory parameters at hospital arrival    
   thrombocytes (x109/l)* 168 (144-191) 205 (165-227) 161 (134-188)
   haemoglobin (g/l)* 153 (133-163) 145 (139-155) 136 (125-141)
Survival    
   hospital discharge 5 (71%) 5 (71%) 16 (73%)
   30 days 5 (71%) 5 (71%) 14 (64%)
   1 year 5 (71%) 4 (57%) 13 (59%)
  1. * = median value (IQR), ICH = intracranial haemorrhage, BP = blood pressure, UFH = unfractionated heparin, LMWH = low molecular weight heparin, i.v. = intravenously, s.c. = subcutaneously.
\